

June 14, 2018

BSE Limited, Department of Corporate Services, P. J. Towers, Dalal Street, Mumbai Samachar Marg, <u>MUMBAI - 400 001</u>.

The National Stock Exchange of India Ltd., Exchange Plaza, Bandra Kurla Complex, Bandra (East), <u>MUMBAI - 400 051</u>.

Dear Sir/Madam,

### Sub: <u>Disclosure pursuant to Regulation 30 of the SEBI</u> (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Enclosed is a Press Release as regards receipt final USFDA approval for Drospirenone, Ethinyl Estradiol, Levomefolate Calcium Tablets and Levomefolate Calcium Tablets, 3 mg/0.02 mg/0.451 mg and 0.451 mg, to market a generic version of Bayer HealthCare Pharmaceutical Inc.'s Beyaz<sup>®</sup> Tablets.

This may kindly be considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Thanking you,

Yours faithfully, For **LUPIN LIMITED** 



Encl.: a/a



LUPIN LIMITED

Registered Office: 3rd Floor, Kalpataru Inspire, Off W. E. Highway, Santacruz (East), Mumbai - 400 055 India. Tel : (91-22) 6640 2323.Corporate Identity Number: L24100MH1983PLC029442www.lupin.com

1.18			1		( Section of the sect			
1.17	441	ન્દ્ર નશ	151	r = 1	1 .		1.1	-
Pi	8 - m	(74))))))))))))))))))))))))))))))))))))	1 6 1	100	1	e (	A 1 -	-



BSE: 500257 NSE: LUPIN

REUTERS: LUPIN.BO

BLOOMBERG: LPC IN

# Lupin receives FDA approval for generic Drospirenone, Ethinyl Estradiol, Levomefolate Calcium Tablets and Levomefolate Calcium Tablets, 3 mg/0.02 mg/0.451 mg and 0.451 mg

**Mumbai, Baltimore, June 14, 2018:** Pharma major Lupin announced that it has received final approval for its Drospirenone, Ethinyl Estradiol, Levomefolate Calcium Tablets and Levomefolate Calcium Tablets, 3 mg/0.02 mg/0.451 mg and 0.451 mg, from the United States Food and Drug Administration (FDA) to market a generic version of Bayer HealthCare PharmaceuticalInc.'s (Bayer) Beyaz® Tablets.

Lupin's Drospirenone, Ethinyl Estradiol, Levomefolate Calcium Tablets and Levomefolate Calcium Tablets, 3 mg/0.02 mg/0.451 mg and 0.451 mg, are the generic equivalent of Bayer's Beyaz<sup>®</sup> Tablets. It is indicated for use by women to:

- prevent pregnancy;
- treat symptoms of premenstrual dysphoric disorder (PMDD) for women who choose to use an oral contraceptive for contraception;
- treat moderate acne for women at least 14 years old, only if the patient desires an oral contraceptive for birth control; and
- raise folate levels in women who choose to use an oral contraceptive for contraception

Drospirenone, Ethinyl Estradiol, Levomefolate Calcium Tablets and Levomefolate Calcium Tablets, 3 mg/0.02 mg/0.451 mg and 0.451 mg had annual sales of approximately USD 82.2 million in the US (IQVIA MAT April 2018).

## **About Lupin Limited**

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB'segment.

Lupin is the 12<sup>th</sup> and 8<sup>th</sup> largest generics pharmaceutical company by market capitalization (31<sup>st</sup> March 2018, Bloomberg) and revenues (31<sup>st</sup> December 2017, Bloomberg LTM) respectively. The Company is the 4<sup>th</sup> largest pharmaceutical player in the US by prescriptions (IQVIA MAT March 2018); 3<sup>rd</sup> largest Indian pharmaceutical company by global revenues (31<sup>st</sup> December 2017, Bloomberg LTM); 6<sup>th</sup> largest generic pharmaceutical player in Japan and 5<sup>th</sup> largest company in the Indian Pharmaceutical Market (IQVIA MAT March 2018).

For the financial year ended 31<sup>st</sup> March, 2018, Lupin's Consolidated sales and Net profits were at Rs. 155,598 million (USD 2.41 billion) and Rs. 2,513 million (USD 39 million) respectively. Please visit <u>http://www.lupin.com</u> for more information. You could also follow us on Twitter – <u>www.twitter.com/lupinglobal</u>

CIN: L24100MH1983PLC029442 Registered Office: Lupin Ltd, 3<sup>rd</sup> Floor, Kalpataru Inspire, Off Western Express Highway, Santacruz (East), Mumbai 400 055.

Press Release



#### BSE: 500257

NSE: LUPIN

**REUTERS: LUPIN.BO** 

**BLOOMBERG: LPC IN** 

For further information or queries, please contact -

#### Pooja Thakran

VP - Corporate Communications Email: poojathakran@lupin.com Ph: +91-22-66402531 / 8291013225

Arvind Bothra Head – Investor Relations Email: <u>arvindbothra@lupin.com</u> Ph: +91-22-66402137

\*<u>Safe Harbor Statement</u> Beyaz® is a registered trademark of Bayer Aktiengesellschaft